Key result
Aptamer-based sensors enable real-time in vivo anthracycline monitoring for up to 7 days in rodents.
Why the study?
Anthracyclines carry a narrow therapeutic index and cardiotoxicity risk, but conventional therapeutic drug monitoring cannot resolve the sub-minute concentration dynamics that determine organ-specific drug exposure.
Do electrochemical aptamer-based sensors enable real-time in vivo pharmacokinetic monitoring of anthracycline chemotherapeutics compared to conventional sampling?
Do electrochemical aptamer-based sensors enable real-time in vivo pharmacokinetic monitoring of anthracycline chemotherapeutics compared to conventional sampling?
Electrochemical aptamer-based sensors provide high-resolution, real-time in vivo pharmacokinetic monitoring of anthracyclines in preclinical models, offering a potential future strategy to personalize dosing and minimize cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Enables real-time anthracycline TDM in patients; leaves open whether it improves dosing safety or outcomes.
Zhang et al. (2026) conducted a review in Oncology (Anthracycline chemotherapy). Electrochemical aptamer-based (EAB) sensors vs. Conventional therapeutic drug monitoring was evaluated. Electrochemical aptamer-based sensors enable real-time in vivo pharmacokinetic monitoring of anthracyclines, resolving a 30-60 min plasma-to-ISF lag at 12 s resolution in rodent models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: